

# PATIENT ACCESS TO DIAGNOSTIC TESTING

- Hospital laboratory/Reference lab
- Satellite laboratories or STAT labs
- Emergency Room/Operating Room/ICU
- Physician Office Labs (POL)
- Urgent Care Centers
- Cardiology Care Centers
- Community/ Pharmacy
- Home Use



**Shift to near patient testing allows for earlier detection,  
diagnosis and monitoring**

**DISTRIBUTED BY: JANT PHARMACAL CORPORATION**

16530 VENTURA BLVD., STE 512, ENCINO, CA 91436


TEL 800.676.5565 FAX 818.986.0235

INFO@JANTDX.COM WWW.JANTDX.COM

## Unique Random Access

Ability to run 6 different tests for 6 different patients *simultaneously*

Tests may be started at any time



## Ease of Use

- Workflow easier than lab based system
- Plug and play design, no installation required
- No sample centrifugation needed

## Intuitive Touchscreen Interface

- Bright easy to read display
- Multi-language capability
- LIS connectivity

## High Security

- Multiple access levels
- Operator lockout
- LQC lockout


## Maximized Efficiency

- Throughput: 6 different tests on 6 different patients can be performed simultaneously
- Random access ports
- Modular, expandable design

## Extraordinary Quality

- No calibration or maintenance required
- Self diagnostic and Internal quality checks
- Accurate, precise results in ~15 min

## Small Footprint



# HEART FAILURE TREATMENT - ENTRESTO

Novartis launched Entresto (LCZ696) which gained early FDA approval in 2015 (ARB-NEP inhibitor)


CARDIOVASCULAR 12.26.2015

## 5 Game-Changers in Cardiology in 2015: Entresto

— Novartis heart failure drug cited as 'breakthrough'



**PARADIGM-HF trial showed reduced cardiovascular mortality and hospitalization in HFrEF patients**






# NT-PROBNP IN PATIENTS ON ENTRESTO

## Monitoring Treatment

- The new drug *Entresto* does not directly affect the biologically inactive NTproBNP allowing for the effective monitoring of treatment.



**In PARADIGM-HF, Entresto led to early and sustained reduction in NT-proBNP levels, whereas BNP levels rose relative to control**



# COMPELLING PRODUCT HIGHLIGHTS

---

- Proprietary technology platform with unique competitive advantage
  - No calibration, maintenance or servicing required
  - Portable and/or high volume testing options
- Wide range of markets and tests available
- Quality and compliance features built-in
- Speed, Precision, Accuracy
- **NT-pro BNP** on a POC platform

**DISTRIBUTED BY: JANT PHARMACAL CORPORATION**

16530 VENTURA BLVD., STE 512, ENCINO, CA 91436

TEL 800.676.5565 FAX 818.986.0235

INFO@JANTDX.COM WWW.JANTDX.COM

